Previous Article | Next Article 
Journal of Clinical Microbiology, April 2001, p. 1494-1500, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1494-1500.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Development of an Immunoassay for Rapid Detection of Ganglioside
GM1 Mimicry in Campylobacter jejuni
Strains
Martina M.
Prendergast,1
Timo U.
Kosunen,2 and
Anthony P.
Moran1,*
Department of Microbiology, National
University of Ireland, Galway, Ireland,1
and Department of Bacteriology and Immunology, University
of Helsinki, Finland2
Received 4 October 2000/Returned for modification 14 December
2000/Accepted 26 January 2001
 |
ABSTRACT |
Mimicry of peripheral nerve gangliosides by Campylobacter
jejuni lipopolysaccharides (LPSs) has been proposed to
induce cross-reacting antiganglioside antibodies in
Guillain-Barré syndrome (GBS). Because current methods for LPS
characterization are labor-intensive and inhibit the screening of large
numbers of strains, a rapid GM1 epitope screening assay was
developed. Biomass from two agar plates of confluent growth yielded
sufficient LPS using a novel phenol-water and ether extraction
procedure. Extracts of LPS were reacted with cholera toxin
(GM1 ligand), peanut agglutinin (Gal
1
3GalNAc ligand),
and anti-GM1 antibodies. After the assay was validated, 12 of 59 (20%) C. jejuni serostrains, including four
serotypes that have not previously been associated with GBS, reacted
with two or more anti-GM1 ganglioside reagents.
Subsequently, LPS extracts from 5 of 7 (71%) C. jejuni
isolates and 2 of 3 (67%) C. jejuni culture collection
strains bore GM1 structures. Overall, the assay system was
reliable, efficient, and reproducible and may be adapted for
large-scale epidemiological studies.
 |
INTRODUCTION |
There is mounting evidence that
Campylobacter jejuni, a causative agent of enteritis, plays
a significant role in the development of Guillain-Barré syndrome
(GBS), a demyelinating disease of the peripheral nervous system
(26, 33, 49, 51). Several variants of GBS occur and
include the demyelinating form called acute inflammatory demyelinating
polyneuropathy (AIDP), the axonal form represented by acute motor
axonal neuropathy (AMAN), and an ocular variant termed Miller Fisher
syndrome (MFS) (18, 34). Characteristically, 76% of AMAN
and 42% of AIDP patients have serologic evidence consistent with
recent C. jejuni infection (18, 27).
O (Penner) serotyping distinguishes between C. jejuni
strains on the basis of differences in the saccharide structure (O side chain and core oligosaccharide [OS]) of the lipopolysaccharide (LPS)
of the bacterium (28, 38, 41). Some reports suggest that
only specific C. jejuni serotypes are associated with GBS (30, 45). In a Japanese study, 81% of C. jejuni isolates from GBS patients belonged to serotype O:19
(20), and, other studies have shown an association with
other serotypes (19, 31, 33, 37, 45, 48, 58). Autoreactive
antibodies to gangliosides, especially GM1, are found in
30% of GBS patient sera, particularly after C. jejuni
infection (15, 19, 26, 35, 36, 49, 58, 59, 63). Thus, it
is currently hypothesized that antiganglioside antibodies may be
induced as a result of molecular mimicry of peripheral nerve
gangliosides by structurally similar C. jejuni LPSs
(49, 59).
Furthermore, since anti-GM1 antibodies in human sera are
likely to be a contributory factor in GBS development, an important step in elucidating the pathogenesis of the disease is determining the
structure of the immunogenic epitopes in ganglioside-mimicking C. jejuni LPS. However, the LPSs from only a few
C. jejuni GBS or MFS isolates have been studied at the
chemical level to determine the precise nature of the ganglioside-like
structures (3, 5, 7, 8, 10, 29, 39, 48, 61). Methods used
for detecting and analyzing LPS are both labor-intensive and
time-consuming. The major difficulty is that large amounts of LPS are
required for chemical characterization, and this does not allow for the screening of large numbers of strains. However, serological analysis using antiganglioside antibodies and ligands has proven a useful approach for analysis of mimicry in C. jejuni LPS (39,
40, 49). Importantly, although GBS-associated strains can
express high-molecular-weight (high-Mr) LPS
(5, 6, 7), serological analysis using thin-layer
chromatography (TLC) can detect ganglioside mimicry in the core OS of
LPS (39, 40, 49).
The aim of this study was to develop a rapid screening test to detect
strains that have a GM1-like epitope in their LPSs. The
assay combined a rapid miniphenol-water extraction procedure with TLC
and immunostaining. The conformation of the carbohydrate moiety of
glycolipids is best preserved in TLC, which is thus an appropriate
technique for an assay examining reactions of antibodies with LPS. The
novel assay system was validated by comparing the data from binding
studies using purified LPS with results obtained using LPSs extracted
by the rapid method from the same C. jejuni strains. Only a
limited number of serotypes have been found in association with GBS,
and to answer the question whether ganglioside-like epitopes are
limited to a few C. jejuni serotypes, a collection of
C. jejuni serostrains was screened for the GM1
epitope using the new assay system. Finally, the technique was
applied to the rapid screening of clinical isolates from GBS and
enteritis patients.
(A preliminary report of this research was presented at the 10th
International Workshop on Campylobacter, Helicobacter and Related Organisms, Baltimore, Md., 12 to 16 September 1999.)
 |
MATERIALS AND METHODS |
Bacterial strains and growth conditions.
Details of the
C. jejuni culture collection strains and clinical isolates,
as well as strains of Helicobacter pylori and
Escherichia coli used in this study, are given in Table
1. In addition, 59 C. jejuni
serostrains were also included in the study. C. jejuni and
H. pylori strains were routinely grown on blood agar
(Columbia Agar Base [Oxoid Ltd., London, England] with 10% unlysed
horse blood) at 37°C for 48 h in a H2-enriched
microaerobic atmosphere (GasPak BR38 [Oxoid] without a catalyst)
according to an established protocol (22). E. coli strain J5 was grown in an aerobic atmosphere on tryptone soya
agar (Oxoid) at 37°C for 24 h. C. jejuni strains used
for validation purposes (Table 2) were grown on blood agar in a manner
identical to that described above. Bacterial biomass was harvested, and
bulk extraction of LPS was performed by the hot phenol-water extraction
procedure as described previously (32, 55).
Biotyping and serotyping.
Bacterial identification was
carried out by established procedures (28, 41, 52).
Serotyping on the basis of thermostable somatic O antigens was
performed with the 66 antisera of the Penner scheme (41)
and an additional 30 antisera to new serotypes not included in the
Penner scheme.
Extraction of LPS using a miniphenol-water extraction
procedure.
Biomass harvested from two agar plates with confluent
growth was washed three times in phosphate-buffered saline (PBS; pH 7.4; Oxoid) by centrifugation (5,000 × g for 5 min)
and resuspended in 3.0 ml of sterile PBS (25). An aliquot
of 0.75 ml was removed, centrifuged as before, and resuspended in 0.75 ml of water. An equivalent volume of 90% phenol (preheated to 65°C)
was added, and samples were mixed for 1 min using an autovortex mixer
and then incubated for 10 min at 65°C. At regular intervals the
samples were mixed and, after cooling on ice, the samples were
centrifuged (12,000 × g for 3 min). At this stage,
separated layers were visible in the suspension. Residual phenol was
removed from the aqueous phase by extracting three times with diethyl
ether. The diethyl ether phase was discarded, and the water phase
(containing the LPS) was placed in a fume cupboard for 1 h to
allow the remaining diethyl ether to evaporate.
Comparison of LPS extraction techniques.
To rule out the
possibility that LPS extraction by the miniphenol-water procedure and
LPS extraction by the hot phenol-water technique result in the
purification of different subpopulations of LPS, materials extracted by
the two methods were compared. Preparations of LPS were examined by
polyacrylamide gel electrophoresis (PAGE) with silver staining, by
immunoblotting, and by TLC with immunostaining with the ligands cholera
toxin (CT), peanut agglutinin (PNA), and anti-GM1
antibodies. Furthermore, modifications of the miniphenol-water
extraction procedure were performed with four C. jejuni
strains, and the resulting material was included in the comparative
studies. First, purified LPS (1.5 mg) was added to harvested C. jejuni biomass and a miniphenol-water extraction was performed on
the resulting material. Second, a miniphenol-water extraction was
performed on a pure LPS solution (2 mg/ml). Third, miniphenol-water-extracted LPS was subjected to enzymatic digestion with 80 µg of proteinase K (Sigma Chemical Co., St. Louis, Mo.) for
1 h at 60°C (17). Fourth, 0.2 mg each of DNase II
(Sigma) and RNase A (Sigma) were incubated at 37°C overnight with the proteinase K-digested LPS extracts, and samples were then treated with
proteinase K (0.8 mg). In addition, proteinase K-treated whole-cell
(PKWC) extracts of C. jejuni strains were prepared as
described by Hitchcock and Brown (17). Finally, boiled
lysates were prepared by diluting harvested bacteria in PBS (pH 7.4) to an A600 of 0.3, followed by centrifugation
(5,000 × g) and solubilization of the resulting pellet
in 200 µl of PBS (for TLC) or in 200 µl of electrophoresis lysing
buffer at 100°C for 1 h.
Additionally, we compared the LPS staining patterns of C. jejuni miniphenol-water-extracted LPS, pure LPS, and LPS prepared as described by Blake and Russell (12) by using the
extraction procedure of Al-Hendy et al. (1).
SDS-PAGE and immunoblotting.
The discontinuous buffer system
of Laemmli (21) was used to fractionate LPS extracts by
sodium dodecyl sulfate (SDS)-PAGE using a stacking gel of 5%
acrylamide and a separation gel of 15% acrylamide containing 3.2 M
urea (BDH Laboratory Supplies, Poole, England) (39). After
SDS-PAGE, the gels were fixed and the LPS was visualized by silver
staining as described previously (54). Alternatively, LPSs
fractionated by SDS-PAGE were electrotransferred from gels to
nitrocellulose membranes (pore size, 0.45 µm; Bio-Rad Laboratories,
Hercules, Calif.) (53). H. pylori LPS on
nitrocellulose blots was visualized with an anti-Lewis Y monoclonal
antibody (Signet Laboratories, Inc., Dedham, Mass.) against the O side chain (11) as the first antibody and horseradish
peroxidase (HRP)-conjugated anti-mouse immunoglobulin M (IgM) (Sigma)
as the second antibody. Alternatively, for detection of E. coli LPS reactions, a monoclonal antibody to E. coli
core OS (anti-R3) was used as the first antibody (2) and
an HRP-conjugated anti-mouse IgG (Sigma) was used as the second antibody.
TLC.
Gangliosides (1-µg aliquots; Sigma) and LPS extracts
(5-µl aliquots) were analyzed by TLC on precoated silica gel 60 glass plates (Merck, Darmstadt, Germany). Solvent systems consisting of
chloroform-methanol-0.22% CaCl2 · 2H2O (50:45:10 [vol/vol/vol]) (47) and
n-propanol-water-25% NH4OH (60:30:10
[vol/vol/vol]) (49, 59) were used as developers for
gangliosides and LPSs, respectively. Gangliosides and LPS were
visualized by spraying plates with resorcinol-HCl reagent
(50).
Immunostaining.
TLC with immunostaining was performed using
the procedure of Saito et al. (47) as modified by Schwerer
et al. (49). Briefly, developed TLC plates were dried for
30 min in a vacuum desiccator, fixed in 0.2% polyisobutylmethacrylate
(Aldrich, Steinheim, Germany) in n-hexane (Merck) for
1.5 min, and dried as before. Nonspecific binding was reduced by
submerging the plates for 1 h in a solution of PBS containing
0.3% gelatin (gelatin-PBS). Subsequently, lanes were overlaid with
rabbit antiserum to ganglioside GM1 (Matreya Inc., Pleasant
Gap, Pa.), diluted 1:100 in gelatin-PBS. Plates were incubated at 4°C
overnight, washed three times with cold PBS, overlaid with
peroxidase-conjugated anti-rabbit IgG (Sigma) diluted 1:500 in
gelatin-PBS, and incubated at room temperature for 1 h with gentle
rocking. The plates were washed with cold PBS, and the immunoreactants
were visualized by use of an HRP development system (Bio-Rad
Laboratories). Control experiments for antibody binding were performed
whereby (i) preimmune rabbit serum was used instead of
anti-GM1 antiserum and (ii) TLC plates were overlaid with
the second antibody but not with the first antibody. Binding studies
with CT-peroxidase conjugate (Sigma) and PNA-peroxidase conjugate
(Kem-En-Tec, Copenhagen, Denmark) were performed under the same
conditions as those described for immunostaining. However, only one
overlay step with peroxidase-conjugated CT (1 µg/ml) or PNA (20 µg/ml) was necessary. Control experiments for CT and PNA ligand
binding were performed using tetanus toxin C (TTC, which binds to
disialosyl, or B series, gangliosides), which does not react with
ganglioside GM1, instead of CT or PNA.
 |
RESULTS |
Assay validation.
Silver-stained SDS-PAGE gels comparing
miniphenol-water-extracted LPSs, LPSs extracted by a modification
of that procedure, and pure (hot phenol-water-extracted) LPSs from
C. jejuni serostrains O:19 and O:2, and from two
serotype O:41 strains (16971.94GSH and 28134.94GSH),
exhibited a pattern of bands migrating near the bottom of the gel.
These bands corresponded to low-Mr rough-form LPS composed of core OS and lipid A (Fig.
1A). As C. jejuni
high-Mr LPS is not visualized by the
silver-staining procedure of Tsai and Frasch (54),
immunoblotting was performed with C. jejuni typing antisera
(41). High-Mr LPS was visualized
for C. jejuni serostrain O:19, but as with silver
staining, only low-Mr LPS was apparent for
C. jejuni O:2 and serotype O:41 strains (data not shown).
Within the same strain, the miniphenol-water-extracted LPS, LPSs
extracted by a modification of that procedure, and pure LPS had
identical banding profiles, demonstrating that the different extraction
procedures and modifications used do not select for different
subpopulations of LPS. In addition, the pattern of staining in the
low-Mr region of the gel of the LPS extracted by
the method of Blake and Russell (12) was identical to the
profiles of both miniphenol-water-extracted LPS and purified LPS from
the same strain (data not shown). Similarly, for each individual strain of the four C. jejuni strains described above, there were no
differences in ligand or antibody affinities between LPS extracts
regardless of the extraction procedure used. As shown in Fig. 1B,
CT showed the same reactivity for each LPS extract, with the exception
of a weaker reaction with the boiled extract and PKWC lysate. The weaker reaction of boiled and PKWC lysates was a consistent finding with all the C. jejuni strains and ligands used; it
potentially reflects the presence of contaminating proteins. Supporting
this, Coomassie blue-stained SDS-PAGE gels of each preparation
demonstrated the presence of proteins in boiled extracts and PKWC
lysates, but not in the miniphenol-water LPS extracts (data not shown). In addition, no reactions were observed on control TLC plates incubated
with preimmune rabbit serum or on plates where the second antibody was
incubated in the absence of the first antibody. Moreover, immunoblots
of purified LPS and miniphenol-water-extracted LPS from H. pylori NCTC 11637 and E. coli J5 (UK) showed identical patterns of binding to corresponding antibodies, regardless of the LPS
extraction procedure used (data not shown).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 1.
Silver stained SDS-PAGE gels (10-µl aliquots) (A) and
binding of CT (5-µl aliquots) (B) to LPS extracts of C. jejuni NCTC 11168. (A) Lanes: 1, miniphenol-water-extracted LPS
with added purified LPS; 2, miniphenol-water-extracted and
DNase-RNase-proteinase K-treated LPS; 3, boiled extract; 4, PKWC
extract; 5, pure LPS with miniphenol-water extraction; 6, pure LPS (1 µg); 7, miniphenol-water LPS. (B) Lanes: 1, C. jejuni O:3
pure LPS; 2, miniphenol-water- and proteinase K-treated LPS; 3, miniphenol-water-extracted LPS; 4, pure LPS (1 µg); 5, boiled
extract; 6, PKWC extract.
|
|
Purified LPS and miniphenol-water-extracted LPS from nine C. jejuni strains were available (Table
2), and by comparing the reactions of
these LPSs with CT, PNA, and anti-GM1 antibodies, it was
possible to further validate the assay system. For each individual
strain, LPSs from the miniphenol-water extraction method gave the same
results for CT binding as purified LPSs, to within one degree of
positivity (Table 2). Therefore, based on CT binding, good correlation
was observed for pure LPS and LPS extracted by the
miniphenol-water, or rapid, method. In addition, with respect to the reactions of pure LPS and miniphenol-water-extracted LPS with
PNA, the results correlated well for 6 of 9 (67%) strains. However,
purified LPSs from serostrain O:19 and from two serotype O:41
strains (260.94RXH and 28134.94GSH) reacted with PNA (Table 2),
but LPS extracted by the rapid method did not reproducibly exhibit a positive reaction with PNA. However, proteinase K
treatment of miniphenol-water-extracted LPS from these three strains
yielded reproducible positive reactions. Polyclonal
anti-GM1 antibodies, which weakly cross-react with
asialo-GM1, GM2, and GD1b
gangliosides (39), reacted with 7 of the 9 (78%) C. jejuni strains tested (Table 2). Moreover, a very good correlation
for binding was observed with LPS of those strains which had been
extracted by both methods. All of the LPSs that reacted with CT also
reacted with anti-GM1 antibodies, with the exception of
serostrain O:4 LPS, which mimics ganglioside GD1a
and reacted with CT only. Although CT is described as a
GM1 ligand, it also cross-reacts with gangliosides which
have a GM1-related structure, e.g., asialo-GM1
and GM2 gangliosides (39, 40, 49). Therefore,
the use of antibodies to ganglioside GM1 in conjunction
with CT appears to be the most efficient way to screen for
GM1 mimicry in C. jejuni strains.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of the reactions of ligands and
anti-GM1 antibodies to pure and
miniphenol-water-extracted LPSs for validation purposes
|
|
To ensure that the rapid assay for screening GM1
epitopes was reproducible, six strains chosen at random were grown,
extracted, and reexamined in the same manner, and identical binding
results were observed on retesting. Overall, the assay system was
reliable, efficient, and reproducible, and its use was validated when
results of binding experiments with LPS extracted by the rapid method were compared to results using purified LPS.
Screening of the collection of C. jejuni
serostrains for the GM1 epitope.
To answer the
question whether ganglioside-like epitopes are carried only by a
limited number of Penner serotypes, a collection of C. jejuni serostrains was screened for the GM1
epitope using the rapid assay system.
As shown in Table 3, LPSs from five
different serostrains reacted with all three ligands (O:4, O:5,
O:13, O:36, and O:44), and isolates of each of these serotypes have
been associated with GBS (7, 9, 14, 31, 33, 39). The LPSs
of two of these C. jejuni serostrains have been
chemically characterized and reported to mimic ganglioside
GD1a (O:4) and ganglioside GM2 (O:36) (3, 10). In our assay, GM1 mimicry was detected in LPS
from serostrain O:13. An isolate of this serotype has recently been
associated for the first time with GBS (14). Furthermore,
strong binding of each of the ligands tested was observed with LPSs of
serostrains O:5 and O:44, suggesting for the first time the
presence of a GM1 structure in the LPSs of these strains.
Serostrain O:2 LPS was negative for reaction with each of the ligands
tested, although LPS of C. jejuni NCTC 11168, an O:2
serotype, was found to bear GM1 mimicry (Table 2),
consistent with the differences observed between these strains
(24). Furthermore, serostrain O:23 LPS did not react
with CT, PNA, or anti-GM1 antibodies, in contrast to
serostrain O:36, despite sharing an identical core OS structure. This indicates a difference in GM2 ganglioside epitope
expression in the two serostrains, and it can be proposed that the
O side chain may have an effect on the expression of core OS in
serostrains O:23 and O:36 (6). Also, the C. jejuni AZR6491 isolate (serotype O:23) reacted with CT in the
validation study (Table 2). This suggests that the core OS of
serostrain O:23 LPS may be different from that of LPSs from
C. jejuni isolates of the same serotype, which is consistent
with our preliminary chemical studies (5) and which has
also been observed previously with C. jejuni O:19 isolates
(7).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Binding of ligands and anti-GM1 antibodies to
serostrain C. jejuni LPSs extracted using the
miniphenol-water procedurea
|
|
Overall, the LPSs of seven serostrains reacted with
anti-GM1 antibodies and one other ligand: three with CT
(O:19, O:41, and O:42) and four with PNA (O:14, O:25, O:34, and O:43).
The LPSs from serotype O:19 and O:41 strains are known to exhibit
mimicry of ganglioside GM1 (7, 39), whereas
serostrain O:42 LPS has not been chemically characterized. The
results of this assay strongly suggest that the LPS of this
serostrain bears a GM1-related structure. Anti-GM1 antibodies and PNA both cross-react with
asialo-GM1 ganglioside, and thus it was deduced that LPS
from serostrains O:14, O:25, O:34, and O:43 may have LPSs which
mimic asialo-GM1 ganglioside.
As shown in Table 3, LPSs from seven serostrains reacted with only
one ligand, and six of these reacted only weakly with that particular
ligand. Thus, it was considered that LPS from serostrains O:1,
O:20, O:45, O:47, O:48, and O:50 do not mimic ganglioside
GM1. Thus, strains that were weakly positive for only one
ligand were considered not to bear GM1-mimicking structures in their LPSs, and this criterion was assigned as the cutoff value for
absence of GM1 ganglioside mimicry. A strain was considered to exhibit GM1 mimicry if the LPS reacted with two or more
of the ligands tested. However, LPS from serostrain O:10 showed
moderate binding with PNA, and while it was unlikely that this strain
had GM1-bearing LPS, it was considered that the core OS of
this strain had a Gal-GalNAc or Gal-Gal disaccharide.
In our assay, all strains with established GM1 ganglioside
mimicry, such as serotypes O:4, O:19, and O:41, reacted with at least
two of the three ligands tested. Also, the assay detected GM1 mimicry in the LPSs of some serostrains which have
not yet been structurally characterized, such as O:5, O:13, O:14, O:25, O:34, O:42, O:43, and O:44. Overall, 46 serostrains (78%) did not
react with any of the three ligands used or were weakly positive with
one ligand, suggesting that GM1 ganglioside-like
epitopes are carried only by some Penner serotypes.
Screening for GM1 mimicry in C. jejuni
enteritis and GBS isolates.
The rapid assay technique was applied
to the testing of the C. jejuni isolates shown in Table
4. Based on reactions with CT, PNA, and
anti-GM1 antibodies, 3 of 5 (60%) serotype O:41 GBS isolates gave reactions that would be expected for the presence of
GM1-like mimicry. However, LPS preparations, including pure LPSs, from two C. jejuni O:41 GBS isolates (319.95 and
367.95) did not appear to exhibit a GM1 ganglioside
structure. Therefore, LPSs from these strains were tested for reaction
with anti-asialo-GM1, anti-GD2,
anti-GD3, and anti-GM2 antibodies and with a
ligand that binds to B series, or disialosyl, gangliosides. However, LPSs from both strains failed to react with any of the ligands tested,
indicating that LPSs from these strains do not resemble gangliosides
such as GM1, GM2, GD2,
GD3, and asialo-GM1. The possibility that LPSs
from these two serotype O:41 strains could mimic ganglioside GD1a cannot be ruled out. Although CT, PNA, and
anti-GM1 antibodies do not react with ganglioside
GD1a (39), all three ligands recognized LPS
from serostrain O:4, which exhibits mimicry of ganglioside GD1a (Table 3). However, microheterogeneity is present in
this LPS, with ~10% of the core OS molecules exhibiting
GM1 mimicry (3, 10), and thus the presence of
a GM1 epitope in serostrain O:4 LPS, rather than an
ability of the reagents to recognize GD1a epitopes,
accounts for the recognition by these three assay reagents. As ligands
for detecting mimicry of ganglioside GD1a are not
commercially available, whether the LPSs from the two serotype O:41
strains mimic ganglioside GD1a remains unanswered.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Binding of ligands and anti-GM1 antibodies to
LPSs of C. jejuni isolates extracted using the
miniphenol-water technique
|
|
As shown in Table 4, the presence of GM1 mimicry in the
LPSs of the two serotype O:41 non-GBS isolates (212.95 and 238.95) indicates the occurrence of ganglioside mimicry without the development of GBS. Similarly, the serotype O:13 enteritis isolate, C. jejuni CCUG 8680, reacted with all three ligands, and thus the LPS
from this strain has GM1 ganglioside mimicry.
Interestingly, serostrain O:13 LPS (Table 3) also exhibited a
GM1-related structure. It is proposed that C. jejuni CCUG 6951 (O:1), also an enteritis isolate, mimics
asialo-GM1 ganglioside, as the LPS reacted only with CT and
PNA, but not with anti-GM1 antibodies. Thus, some uncomplicated enteritis isolates have LPSs bearing ganglioside-like structures, suggesting that host responses to the ganglioside molecules
are important in determining the outcome of Campylobacter infection.
 |
DISCUSSION |
The association of GBS with preceding infection has led to a
search for candidate bacterial antigens which may precipitate autoimmune responses in the host (16, 42, 56, 57).
Gangliosides have been extensively studied as possible host antigens
for autoimmune disease, since serum antibodies against gangliosides,
especially GM1, are found in GBS sera, particularly when
preceded by C. jejuni infection (15, 35, 44, 59, 60,
63). Molecular mimicry of gangliosides by core OSs of certain
C. jejuni serotypes associated with GBS has been established
(5, 7, 8, 10, 29, 31, 32, 56, 61), but LPSs from only a
few C. jejuni GBS or MFS isolates have been studied at the
molecular level. The main difficulty is that large amounts of biomass
are required for LPS isolation, and this has not allowed for the
screening of large numbers of strains. To overcome this problem, a
laboratory-based rapid GM1 screening method that can be
used to screen for cross-reactive epitopes in C. jejuni
isolates was developed in the present study. Once the assay was
validated, it was used to screen for GM1-bearing strains in
a collection of 59 C. jejuni serostrains and was applied to the testing of a number of C. jejuni clinical isolates.
In the validation experiments, miniphenol-water-extracted LPS, LPSs
from modifications of the miniphenol-water procedure, and pure LPS from
the same strain had comparable banding patterns in SDS-PAGE,
demonstrating that miniphenol-water extraction is a suitable LPS
extraction procedure for use in the present study. In addition, LPS
prepared as described by Blake and Russell (12), according
to the procedure of Al-Hendy et al. (1), displayed low-Mr bands similar to those of
miniphenol-water-extracted LPS and pure LPS when loaded at normal
loading concentrations. However, higher loading concentrations (10 µg), as used in the original study of Al-Hendy et al., yielded bands
in the high-Mr region which corresponded to
aggregrates of LPS. Within the same strain, no differences in
ligand or antibody affinities were observed among
miniphenol-water-extracted LPS, LPSs from the miniphenol-water modified
procedures, and pure LPS, again justifying the use of miniphenol-water
extraction in our assay system. Additionally, ligand binding to
ganglioside-mimicking pure LPSs was compared to ligand interactions
with miniphenol-water-extracted LPSs from the same nine strains. In
general, the ganglioside detection reagents had the same specificities
for miniphenol-water-extracted LPSs and pure LPSs. The observation that
PNA binding was reproducible only after proteinase K treatment of
miniphenol-water extracts suggests that the use of this ligand may be
justified only in tests using purer LPS. However, when LPS extraction
was repeated using some of the strains, identical binding results were
observed upon retesting, thus confirming the reproducibility of the
assay. The reliability of the rapid assay was confirmed when
miniphenol-water LPS extracts from strains with known ganglioside-like
structures were tested (5, 39, 40, 49, 59, 61, 62).
Once the assay was validated and shown to be reliable and reproducible,
59 C. jejuni serostrains were screened for
GM1-bearing LPS. Some serostrains with known
ganglioside mimicry reacted with the ligands as expected, e.g.,
serostrains O:4, O:19, and O:36, which is consistent with
GM1 or GM2 mimicry in these strains (7, 10, 29, 59, 62). C. jejuni serotypes that have been
isolated from neuropathy patients and for which no LPS structural data is available include serotypes O:5, O:13, and O:44 and, in this study,
were found to bear GM1-like epitopes. Based on
recognition of PNA and anti-GM1 antibodies, LPSs from
serostrains O:14, O:25, O:34, and O:43 were considered to exhibit
asialo-GM1 mimicry. Interestingly, none of these serotypes
have yet been found in association with GBS, although, to date, all
neuropathy-associated strains bear LPSs which are sialylated.
Overall, 46 of 59 serostrains (78%) either failed to react with
any of the three ligands used or were weakly positive with one ligand,
suggesting that GM1 ganglioside-like epitopes are carried only by some Penner serotypes, which may account for the limited number of serotypes found in association with GBS. However, of
the 46 serostrains that failed to react with any of the ligands tested, 11 have been found in association with GBS: serostrains O:1, O:2, O:15, O:16, O:18, O:20, O:23, O:24, O:30, O:37, and O:53
(31, 33). It is thought that the LPSs from these serotypes mimic more complex gangliosides that could not be detected with the
reagents used in the present study. On the other hand, no serostrain with known GM1 mimicry failed to react with
CT in combination with anti-GM1 antibodies, thus justifying
the use of the rapid assay for GM1 screening of C. jejuni strains.
Subsequently, the assay was used for the screening of C. jejuni GBS and enteritis isolates for GM1 mimicry. The
majority of the GBS-associated serotype O:41 strains had
GM1-like structures in their LPSs, which is consistent with
the GM1 mimicry previously reported for serotype O:41
GBS-associated strains (39, 40). Of the
enteritis-associated strains, half had LPSs which had GM1 epitopes, and thus mimicry of ganglioside GM1 by core
OS of C. jejuni strains is not limited to strains associated
with GBS. This phenomenon has previously been reported by a number of
groups (29, 34, 39, 46, 51). A study by Nachamkin et al.
(34) showed that 26% of enteritis isolates were positive
for the GM1-like epitope. Patients who develop
enteritis and have isolates with ganglioside-mimicking LPS do not
develop antiganglioside antibodies (37, 43, 51). The
humoral immune response to neural cross-reactive epitopes in the
LPSs of C. jejuni appears to be different in GBS than in
uncomplicated enteritis (51). These factors suggest that
other attributes of the host and/or bacterium in addition to
ganglioside mimicry, contribute to the development of GBS or MFS.
The rapid screening assay described here has advantages over other
systems reported previously (34, 46, 51). One assay involved spotting boiled cultures directly onto a nitrocellulose membrane and probing for GM1 epitopes with CT and PNA
(34). First, in our rapid assay system, crude LPSs rather
than boiled lysates are used, and thus there is no interference from
non-LPS constituents. Second, the LPS is separated by TLC using silica as an adsorbent, a system whereby the conformation of the antigenic structure is unaltered, and this is considered not to be the case with
the attachment of LPS to nitrocellulose membranes. Moreover, TLC
separates LPS from contaminating components during the development process. In screening for GM1-bearing strains, Sheikh et
al. (51) used purified LPS extracted by the hot
phenol-water extraction procedure (55) and probed
immunoblotted material with CT, PNA, and TTC. The main limitation of
this assay was efficiency, as it was necessary to produce pure LPS and
immunoblotting was required. Another assay, described by Sack et al.
(46), was based on an inhibitory enzyme-labeled
immunosorbent assay (ELISA) whereby strains with a GM1-like
LPS bind to CT and inhibit the binding of control CT to ganglioside
GM1. However, the assay had the disadvantage that crude
boiled extracts were used, and the assay detected CT binding only,
which can be misleading, and did not detect GM1 epitopes directly. Moreover, CT is a GM1 ligand, but it
also cross-reacts with GM2 and asialo-GM1
gangliosides, and thus some of the strains detected by Sack et al.
(46) may have possessed asialo-GM1 or GM2 epitopes. Nevertheless, the inhibition assay had
the advantage that large numbers of strains could be tested quickly. In
summary, the rapid screening assay described in the present study has
the advantages of being reliable, reproducible, and able to screen large numbers of strains quickly; thus, the assay has attributes attractive for large-scale epidemiology studies.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Irish Health Research
Board (grant 86-95 to A.P.M. and grant 12/99 to M.M.P.).
We thank A. J. Lastovica (Cape Town, South Africa) for providing
the C. jejuni O:41 strains and B. C. Jacobs (Rotterdam,
The Netherlands) for providing the C. jejuni AZR 6491 isolate.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, National University of Ireland, Galway, Ireland. Phone: 353-91-524411. Fax: 353-91-525700. E-mail:
anthonymoran{at}nuigalway.ie.
 |
REFERENCES |
| 1.
|
Al-Hendy, A.,
P. Toivanen, and M. Skurnik.
1991.
Rapid method for isolation and staining of bacterial lipopolysaccharide.
Microbiol. Immunol.
35:331-333[Medline].
|
| 2.
|
Appelmelk, B. J.,
J. J. Maaskant,
A. M. Verweij van Vught,
N. M. van der Meer,
B. G. Thijs, and D. M. McLaren.
1993.
Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.
J. Gen. Microbiol.
139:2641-2647[Medline].
|
| 3.
|
Aspinall, G. O.,
S. Fujimoto,
A. G. McDonald,
H. Pang,
L. A. Kurjanczyk, and J. L. Penner.
1994.
Lipopolysaccharide from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure.
Infect. Immun.
62:2122-2125[Abstract/Free Full Text].
|
| 4.
|
Aspinall, G. O.,
C. M. Lynch,
H. Pang,
R. T. Shaver, and A. P. Moran.
1995.
Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide.
Eur. J. Biochem.
231:570-578[Medline].
|
| 5.
|
Aspinall, G. O.,
A. Mainkar,
M. M. Prendergast,
B. C. Jacobs, and A. P. Moran.
1997.
Lipopolysaccharides from a neuropathy-associated infection from Campylobacter jejuni serotype O:23, p. 93-96.
In
A. J. Lastovica, D. G. Newell, and E. E. Lastovica (ed.), Campylobacter, Helicobacter and related organisms. Institute of Child Health and University of Cape Town, Cape Town, South Africa.
|
| 6.
|
Aspinall, G. O.,
A. G. McDonald, and H. Pang.
1992.
Structures of the O chains from lipopolysaccharides from Campylobacter jejuni serotypes O:23 and O:36.
Carbohydr. Res.
231:13-20[CrossRef][Medline].
|
| 7.
|
Aspinall, G. O.,
A. G. McDonald,
H. Pang,
L. A. Kurjanczyk, and J. L. Penner.
1994.
Lipopolysaccharides of Campylobacter jejuni serotype O:19. Structures of the core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome.
Biochemistry
33:241-249[CrossRef][Medline].
|
| 8.
|
Aspinall, G. O.,
A. G. McDonald,
T. S. Raju,
H. Pang,
L. A. Kurjanczyk, and J. L. Penner.
1993.
Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide.
Eur. J. Biochem.
213:1029-1037[Medline].
|
| 9.
|
Aspinall, G. O.,
A. G. McDonald,
T. S. Raju,
H. Pang,
S. D. Mills,
L. A. Kurjanczyk, and J. L. Penner.
1992.
Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides.
J. Bacteriol.
174:1324-1332[Abstract/Free Full Text].
|
| 10.
|
Aspinall, G. O.,
A. G. McDonald,
T. S. Raju,
H. Pang,
A. P. Moran, and J. L. Penner.
1993.
Chemical structure of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides.
Eur. J. Biochem.
213:1017-1027[Medline].
|
| 11.
|
Aspinall, G. O.,
M. O. Monteiro,
H. Pang,
E. J. Walsh, and A. P. Moran.
1996.
Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): structure of the O antigen and core oligosaccharide regions.
Biochemistry
35:2489-2497[CrossRef][Medline].
|
| 12.
|
Blake, D. C., and R. G. Russell.
1993.
Demonstration of lipopolysaccharide with O-polysaccharide chains among different heat-stable serotypes of Campylobacter jejuni by silver staining of polyacrylamide gels.
Infect. Immun.
61:5384-5387[Abstract/Free Full Text].
|
| 13.
|
Butzler, J. P.,
P. Dekeyser,
M. Detrain, and F. Dehaen.
1973.
Related vibrio in stools.
J. Pediatr.
82:493-495[CrossRef][Medline].
|
| 14.
|
Endtz, H. P.,
C. W. Ang,
N. van den Braak,
B. Duim,
A. Rigter,
L. J. Price,
D. L. Woodward,
F. G. Rodgers,
W. M. Johnson,
J. A. Wegenaar,
B. C. Jacobs,
H. A. Verbrugh, and A. Belkum.
2000.
Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.
J. Clin. Microbiol.
38:2297-2301[Abstract/Free Full Text].
|
| 15.
|
Gregson, N. A.,
S. Koblar, and R. A. C. Hughes.
1993.
Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features.
Q. J. Med.
86:111-117[Abstract/Free Full Text].
|
| 16.
|
Griffin, J. W., and T. W. H. Ho.
1993.
The Guillain-Barré syndrome at 75: the Campylobacter connection.
Ann. Neurol.
34:125-127[CrossRef][Medline].
|
| 17.
|
Hitchcock, P. J., and T. M. Brown.
1983.
Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.
J. Bacteriol.
154:269-277[Abstract/Free Full Text].
|
| 18.
|
Ho, T. W.,
B. Mishu,
C. Y. Li,
C. Y. Gao,
D. R. Cornblath,
J. W. Griffin,
A. K. Asbury,
M. J. Blaser, and G. M. McKhann.
1995.
Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.
Brain
118:597-605[Abstract/Free Full Text].
|
| 19.
|
Jacobs, B.,
H. Endtz,
F. G. A. van der Meché,
M. P. Hazenberg,
H. A. M. Achtereekte, and P. A. van Doorn.
1995.
Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome.
Ann. Neurol.
37:260-264[CrossRef][Medline].
|
| 20.
|
Kuroki, S.,
T. Saida,
M. Nukina,
T. Haruta,
M. Yoshiota,
Y. Kobayashi, and H. Nakanishi.
1993.
Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain -N-acetylglucosamine residues.
Ann. Neurol.
33:243-247[CrossRef][Medline].
|
| 21.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[CrossRef][Medline].
|
| 22.
|
Lastovica, A. J.,
E. A. Goddard, and A. C. Argent.
1997.
Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains.
J. Infect. Dis.
176(Suppl. 2):139-143.
|
| 23.
|
Lindblom, G. B.,
B. Kaijser, and E. Sjogren.
1989.
Enterotoxin production and serogroups of Campylobacter jejuni and Campylobacter coli from patients with diarrhea and from healthy laying hens.
J. Clin. Microbiol.
27:1272-1276[Abstract/Free Full Text].
|
| 24.
|
Linton, D.,
A. V. Karlyshev,
P. G. Hitchen,
H. R. Morris,
A. Dell,
N. A. Gregson, and B. W. Wren.
2000.
Multiple N-acetylneuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide.
Mol. Microbiol.
35:1120-1134[CrossRef][Medline].
|
| 25.
|
Mills, S. D.,
L. A. Kurjanczyk, and J. L. Penner.
1992.
Antigenicity of Helicobacter pylori lipopolysaccharides.
J. Clin. Microbiol.
30:3175-3180[Abstract/Free Full Text].
|
| 26.
|
Mishu, B., and M. J. Blaser.
1993.
Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome.
Clin. Infect. Dis.
17:104-108[Medline].
|
| 27.
|
Monos, D. S.,
M. Papaioakim,
T. W. Ho,
C. Y. Li, and G. M. McKhann.
1997.
Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome.
J. Infect. Dis.
176(Suppl. 2):180-182.
|
| 28.
|
Moran, A. P., and T. U. Kosunen.
1989.
Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter coli.
APMIS
97:253-260[Medline].
|
| 29.
|
Moran, A. P., and D. T. O'Malley.
1995.
Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome.
J. Endotoxin Res.
2:233-235.
|
| 30.
|
Moran, A. P., and J. L. Penner.
1999.
Serotyping of Campylobacter jejuni based on heat-stable antigens: relevance, molecular basis and implications in pathogenesis.
J. Appl. Microbiol.
86:361-377[CrossRef][Medline].
|
| 31.
|
Moran, A. P.,
M. M. Prendergast, and B. J. Appelmelk.
1996.
Molecular mimicry of host structures by bacterial lipopolysaccharide and its contribution to disease.
FEMS Immunol. Med. Microbiol.
16:105-115[CrossRef][Medline].
|
| 32.
|
Moran, A. P.,
E. T. Rietschel,
T. U. Kosunen, and U. Zahringer.
1991.
Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose.
J. Bacteriol.
173:618-626[Abstract/Free Full Text].
|
| 33.
|
Nachamkin, I.,
B. M. Allos, and T. Ho.
1998.
Campylobacter species and Guillain-Barré syndrome.
Clin. Microbiol. Rev.
11:555-567[Abstract/Free Full Text].
|
| 34.
|
Nachamkin, I.,
H. Ung,
A. P. Moran,
D. Yoo,
M. M. Prendergast,
M. A. Nicholson,
K. A. Sheikh,
T. W. Ho,
A. K. Asbury,
G. M. McKhann, and J. W. Griffin.
1999.
Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States.
J. Infect. Dis.
179:1183-1189[CrossRef][Medline].
|
| 35.
|
Nobile-Orazio, E.,
M. Carpo,
N. Meucci,
M. P. Grassi,
E. Capitani,
M. Sciacco,
A. Mangoni, and G. Scarlato.
1992.
Guillain-Barré syndrome associated with high titres of anti-GM1 antibodies.
J. Neurol. Sci.
109:200-206[CrossRef][Medline].
|
| 36.
|
Obayashi, H.,
T. Saida,
S. Kuroki,
M. Nukina, and Y. Nishitani.
1993.
Guillain-Barré syndrome and Campylobacter jejuni infection.
Shinkei Naika
38:431-438.
|
| 37.
|
Oomes, P. G.,
B. C. Jacobs,
M. P. H. Hazenberg,
J. R. J. Bänffer, and F. G. A. van der Meché.
1995.
Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry.
Ann. Neurol.
38:170-175[CrossRef][Medline].
|
| 38.
|
Penner, J. L.,
J. N. Hennessy, and R. V. Congi.
1983.
Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens.
Eur. J. Clin. Microbiol.
2:78-83.
|
| 39.
|
Prendergast, M. M.,
A. J. Lastovica, and A. P. Moran.
1998.
Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.
Infect. Immun.
66:3649-3655[Abstract/Free Full Text].
|
| 40.
|
Prendergast, M. M.,
H. J. Willison, and A. P. Moran.
1999.
Human monoclonal IgM antibodies to GM1 ganglioside show diverse cross-reactivity with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barré syndrome.
Infect. Immun.
67:3698-3701[Abstract/Free Full Text].
|
| 41.
|
Preston, M. A., and J. L. Penner.
1987.
Structural and antigenic properties of lipopolysaccharide from serotype reference strains of Campylobacter jejuni.
Infect. Immun.
55:1806-1812[Abstract/Free Full Text].
|
| 42.
|
Rees, J. H.,
N. A. Gregson,
P. L. Griffiths, and R. A. C. Hughes.
1993.
Campylobacter jejuni and Guillain-Barré syndrome.
Q. J. Med.
86:623-634.
|
| 43.
|
Rees, J. H.,
N. A. Gregson, and R. A. C. Hughes.
1995.
Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection.
Ann. Neurol.
38:809-816[CrossRef][Medline].
|
| 44.
|
Rees, J. H., and R. A. C. Hughes.
1994.
Campyobacter jejuni and Guillain-Barré syndrome.
Ann. Neurol.
35:248-249[CrossRef][Medline].
|
| 45.
|
Rees, J. H.,
S. E. Soudain,
N. A. Gregson, and R. A. C. Hughes.
1995.
Campylobacter jejuni infection and Guillain-Barré syndrome.
N. Engl. J. Med.
333:1374-1379[Abstract/Free Full Text].
|
| 46.
|
Sack, D. A.,
A. J. Lastovica,
S. H. Chang, and G. Pazzaglia.
1998.
Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin.
J. Clin. Microbiol.
36:2043-2045[Abstract/Free Full Text].
|
| 47.
|
Saito, M.,
N. Kasai, and R. K. Yu.
1985.
In situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates.
Anal. Biochem.
148:54-58[CrossRef][Medline].
|
| 48.
|
Salloway, S.,
L. A. Mermel,
M. Seamens,
G. O. Aspinall,
J. E. Nam Shin,
L. A. Kurjanczyk, and J. L. Penner.
1996.
Miller Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3.
Infect. Immun.
64:2945-2949[Abstract].
|
| 49.
|
Schwerer, B.,
A. Neisser,
R. J. Polt,
H. Bernheimer, and A. P. Moran.
1995.
Antibody cross-reactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome.
J. Endotoxin Res.
2:395-403[Abstract/Free Full Text].
|
| 50.
|
Schwimmer, S., and A. Bevenue.
1956.
Reagent for differentiation of 1,4- and 1,6-linked glucosaccharides.
Science
123:543-544[Free Full Text].
|
| 51.
|
Sheikh, K. A.,
I. Nachamkin,
T. W. Ho,
H. J. Willison,
J. Veitch,
H. Ung,
M. Nicholson,
C. Y. Li,
H. S. Wu,
B. Q. Shen,
D. R. Cornblath,
A. K. Asbury,
G. M. McKhann, and J. W. Griffin.
1998.
Campylobacter jejuni lipopolysaccharide in Guillain-Barré syndrome: molecular mimicry and host susceptibility.
Neurology
51:371-378[Abstract/Free Full Text].
|
| 52.
|
Skirrow, M. B., and J. Benjamin.
1980.
Differentiation of enteropathogenic Campylobacter.
J. Clin. Pathol.
33:1122[Free Full Text].
|
| 53.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 54.
|
Tsai, C. M., and C. E. Frasch.
1982.
A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.
Anal. Biochem.
119:115-119[CrossRef][Medline].
|
| 55.
|
Westphal, O., and K. Jann.
1965.
Bacterial lipopolysaccharides: extraction with phenol water and further applications of the procedure.
Methods Carbohydr. Chem.
5:83-92.
|
| 56.
|
Willison, H. J., and P. G. E. Kennedy.
1993.
Gangliosides and bacterial toxins in Guillain-Barré syndrome.
J. Neuroimmunol.
46:105-112[CrossRef][Medline].
|
| 57.
|
Yuki, N.
1994.
Pathogenesis of axonal Guillain-Barré syndrome: hypothesis.
Muscle Nerve
17:680-682[CrossRef][Medline].
|
| 58.
|
Yuki, N.,
S. Handa,
T. Tai,
M. Takahashi,
K. Saito,
Y. Tsujino, and T. Taki.
1995.
Ganglioside-like epitopes of lipopolysaccharide from Campylobacter jejuni (Pen 19) in three isolates from patients with Guillain-Barré syndrome.
J. Neurol. Sci.
130:112-116[CrossRef][Medline].
|
| 59.
|
Yuki, N.,
S. Handa,
T. Taki,
T. Kasama,
M. Takihashi,
K. Saito, and T. Miyatake.
1992.
Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni.
Biomed. Res.
13:451-453.
|
| 60.
|
Yuki, N.,
S. Sato,
T. Itoh, and T. Miyatake.
1991.
HLA-B35 and acute axonal polyneuropathy following Campylobacter infection.
Neurology
41:1561-1563[Abstract/Free Full Text].
|
| 61.
|
Yuki, N.,
T. Taki,
F. Inagaki,
T. Kasama,
T. M. Takahashi,
M. K. Saito,
S. Handa, and T. Miyatake.
1993.
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.
J. Exp. Med.
178:1771-1775[Abstract/Free Full Text].
|
| 62.
|
Yuki, N.,
T. Taki,
M. Takahashi,
K. Saito,
T. Tai,
T. Miyatake, and S. Handa.
1994.
Penner's serogroup 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope.
Infect. Immun.
62:2101-2103[Abstract/Free Full Text].
|
| 63.
|
Yuki, N.,
H. Yoshino,
S. Sato, and T. Miyatake.
1990.
Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis.
Neurology
40:1900-1902[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, April 2001, p. 1494-1500, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1494-1500.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Alaniz, M. E., Lardone, R. D., Yudowski, S. L., Farace, M. I., Nores, G. A.
(2004). Normally Occurring Human Anti-GM1 Immunoglobulin M Antibodies and the Immune Response to Bacteria. Infect. Immun.
72: 2148-2151
[Abstract]
[Full Text]
-
Prendergast, M. M., Tribble, D. R., Baqar, S., Scott, D. A., Ferris, J. A., Walker, R. I., Moran, A. P.
(2004). In Vivo Phase Variation and Serologic Response to Lipooligosaccharide of Campylobacter jejuni in Experimental Human Infection. Infect. Immun.
72: 916-922
[Abstract]
[Full Text]
-
Nachamkin, I., Liu, J., Li, M., Ung, H., Moran, A. P., Prendergast, M. M., Sheikh, K.
(2002). Campylobacter jejuni from Patients with Guillain-Barre Syndrome Preferentially Expresses a GD1a-Like Epitope. Infect. Immun.
70: 5299-5303
[Abstract]
[Full Text]